← boardnext 2027-06
INKT
MiNK Therapeuticsdistress 2/10 · well-funded / low risk$10.24-7%today-84% from 52w high
Lead: Pneumonia
Revenue
pre-revenue
Liquidity
$10M
Runway
1.5 yrs
Shares 1y
+10%
Price & events
-17.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.5%
1D
-7.7%
1W
-16.4%
1M
-9.7%
3M
-17.2%
6M
-51.4%
1Y
+13.8%
2Y
—
5Y
-91.5%
All
Overview
- Market Cap
- $51.01M
- Volume
- 12.80K
- 52 Week Range
- $7.73 – $64.17
- Total Shares
- 4.98M
- Float Shares
- 1.95M
- Short %
- 4.62%
- % Held by Insiders
- 60.67%
- % Held by Institutions
- 2.63%
- RVOL
- 0.63x
- Beta
- 0.47
Pipeline stages · 1 programs
agenT-797, Standard of Care (SOC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | agenT-797, Standard of Care (SOC) | Pneumonia | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-18HC Wainwright & Co.Buy
- 2026-04-01HC Wainwright & Co.Buy
- 2025-08-15HC Wainwright & Co.Neutral → Buy
- 2025-07-15HC Wainwright & Co.Buy → Neutral
- 2025-07-14William BlairOutperform → Market Perform
- 2025-03-18HC Wainwright & Co.Buy
Competitors — Pneumonia
- none identified
Recent news
- 2026-07-16Here's Why You Should Add INKT Stock to Your Portfolio Now - TradingView
- 2026-07-16What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
- 2026-07-13Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
- 2026-07-10Mink Therapeutics (INKT) Proxy filing Summary - Quartr
- 2026-07-08Mink Therapeutics (INKT) Q1 2025 earnings summary - Quartr
- 2026-06-29MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com
- 2026-06-25INKT Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-17Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.